- Home
- NVS vs NVO Comparison
NVS vs NVO Comparison
Compare NVS & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | NVO |
|---|---|---|
| Founded | 1895 | 1923 |
| Country | Switzerland | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.8B | 212.7B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVS | NVO |
|---|---|---|
| Price | $135.34 | $47.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $118.00 | $54.25 |
| AVG Volume (30 Days) | 1.8M | ★ 18.3M |
| Earning Date | 01-30-2026 | 02-04-2026 |
| Dividend Yield | 1.92% | ★ 2.51% |
| EPS Growth | N/A | ★ 10.06 |
| EPS | ★ 7.30 | 3.67 |
| Revenue | ★ $56,372,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $9.33 | $7.77 |
| Revenue Next Year | $2.75 | $1.86 |
| P/E Ratio | $18.50 | ★ $13.36 |
| Revenue Growth | 12.88 | ★ 16.64 |
| 52 Week Low | $96.06 | $43.08 |
| 52 Week High | $136.66 | $109.88 |
Technical Indicators
Market Signals| Indicator | NVS | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.69 | 45.72 |
| Support Level | $131.77 | $46.08 |
| Resistance Level | $133.84 | $50.75 |
| Average True Range (ATR) | 1.77 | 1.09 |
| MACD | 0.40 | 0.32 |
| Stochastic Oscillator | 74.79 | 38.65 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.